GlassScriptPhysician profile
Kelly C Grow
NPI 1588690382
$12,779.88
in general payments reported to CMS, 2019-2025
41 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $993 · 2021: $1,568 · 2022: $1,906 · 2023: $2,097 · 2024: $2,457 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,064 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,064.23 |
| Education | $185.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,611.04 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,376.90 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,051.31 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $830.22 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $749.51 | 2022-2025 | |
| Celgene Corporation | $651.94 | 2021-2024 | Zeposia |
| Pfizer INC. | $631.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $551.64 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $394.95 | 2019-2024 | Ocaliva |
| Lilly USA, LLC | $316.50 | 2023-2025 | Omvoh, Zepbound |
| Ipsen Biopharmaceuticals, INC | $278.81 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $229.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $187.39 | 2019-2023 | Rebyota |
| Ucb, INC. | $177.98 | 2019-2021 | |
| Ardelyx, INC. | $168.17 | 2022-2025 | Ibsrela |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $163.53 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Ironwood Pharmaceuticals, INC | $159.48 | 2019-2024 | Linzess |
| Mallinckrodt Hospital Products INC. | $135.66 | 2024-2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $118.47 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $107.16 | 2019-2025 | |
| Qol Medical, LLC | $104.01 | 2019-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $100.21 | 2024-2025 | Voquezna |
| Romark Laboratories, Lc | $72.96 | 2019-2020 | |
| Vivus LLC | $70.14 | 2021-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $66.03 | 2021-2023 | |
| Organon LLC | $64.70 | 2024-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $62.03 | 2023-2025 | Zenpep |
| Evoke Pharma, INC. | $59.94 | 2020-2022 | |
| Braintree Laboratories, INC. | $59.89 | 2020-2025 | Sutab, Suflave |
| Amgen INC. | $40.80 | 2023 | Avsola, Amjevita |
| Shionogi INC | $30.83 | 2019 | |
| Redhill Biopharma INC. | $25.90 | 2020 | |
| Sandoz INC. | $19.73 | 2024 | Hyrimoz |
| Novo Nordisk INC | $16.68 | 2025 | Wegovy |
| Allergan, INC. | $16.01 | 2019 | |
| Fresenius Kabi USA, LLC | $15.80 | 2023 | |
| Ethicon US, LLC | $15.45 | 2022 | |
| Medtronic, INC. | $13.78 | 2025 | Interstim |
| Endo Pharmaceuticals INC. | $11.88 | 2019 | |
| Alfasigma USA, INC. | $11.18 | 2020 | |
| Mauna Kea Technologies, INC. | $10.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Grow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.